Validation of the international prognostic index in working formulation group a low-grade non-Hodgkin's lymphoma: retrospective analysis of 137 patients from the Gruppo Italiano per lo studio dei linfomi registry. by Stelitano, C. et al.
Haematologica vol. 85(2):February 2000
Background and Objectives. The subset of non-fol-
licular non-Hodgkin’s lymphoma (NHL) includes
patients with varied prognoses, thus suitable for dif-
ferent therapeutic approaches. The International
Prognostic Index (IPI), originally proposed for
aggressive NHL, has been demonstrated to be of
prognostic relevance also in follicular NHL. The main
aim of the study was to validate the IPI in this his-
tologic category; in addition, the specific prognos-
tic classification, currently employed in the Gruppo
Italiano per lo Studio dei Linfomi (GISL) prospective
therapeutic trials and based on different features,
more similar to those applied to chronic lymphocyt-
ic leukemia, was analyzed.
Design and Methods. The present series consists of
137 evaluable patients affected by Working Formu-
lation group A NHL out of 256 cases referred to the
GISL Registry. The retrospective prognostic study
included the evaluation by both univariate and mul-
tivariate analyses of overall survival, response to
therapy and response duration. The IPI was applied
as originally proposed. The GISL definition of indo-
lent and aggressive disease at diagnosis was based
on the presence of B symptoms, bulky disease, ane-
mia and thrombocytopenia.
Results. The distribution of patients in IPI risk
groups was rather unbalanced with 18%, 47%, 28%
and 7% of cases classified as low (L), intermediate-
low (IL), intermediate-high (IH) and high (H) risk,
respectively. The median overall survival was not
reached in either L or IL risk groups, and was 84.1
and 7.4 months for IH and H risk groups, respec-
tively (p=0.0005). A simplified IPI model was
designed merging patients in both intermediate risk
groups and the statistical difference of survival
retained its significance. GISL prognostic stratifica-
tion was demonstrated to have a significant asso-
ciation with survival, with a median survival of 71.3
months in aggressive disease and a median survival
not reached at 152 months in indolent disease. Both
the simplified IPI model and the GISL risk definition
retained their significance in multivariate analysis
for overall survival, while for response to therapy
only the simplified IPI model resulted to be of sta-
tistical significance. In addition, the GISL prognos-
tic stratification identified patients with different
outcomes within the IPI intermediate risk group,
with a median survival of 70.2 months for patients
with aggressive disease wheras the median survival
for those with indolent disease was not reached.
Finally, a prognostic score resulting from the inte-
gration of the simplified IPI and the GISL system
was statistically validated.
Interpretation and Conclusions. The retrospective
analysis of this series demonstrates the validity of
the IPI in non-follicular indolent NHL and the useful-
ness of integrating the IPI parameters with disease
specific prognostic variables.
©2000, Ferrata Storti Foundation
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Low-grade non-Hodgkin’s lymphoma (NHL)includes different histologic and clinical entities,all characterized by a median overall survival
measurable in years, high sensitivity to radio and
chemotherapy accompanied by a constant tenden-
cy to relapse which makes it almost impossible to
achieve disease eradication.1 In this context, it has
been well demonstrated that the clinical course can
be extremely variable with survival ranging from a
few months to more than a decade. This observation
justifies the application of totally different thera-
peutic approaches ranging from a watch-and-wait pol-
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icy to high dose chemotherapy with stem cell rescue.
Consequently, it would be of great importance to
design a prognostic system able to guide the choice
of the appropriate therapeutic strategy in individual
patients.
Before the extended use of the REAL classification,
which lists each recognized histologic entity,2 low-
grade NHL were grouped into A, B and C categories
of the Working Formulation (WF).3 From the prog-
nostic point of view, many clinical and biological
parameters were reported as influencing the outcome
of these patients and, to some extent, prognostic sys-
tems were proposed.4-6 In addition, the Internation-
al Prognostic Index (IPI), originally conceived for
high-grade NHL,7 has been validated in patients with
low-grade histologies.8-11 The above mentioned expe-
riences dealt either specifically with follicular NHL or
with low-grade NHL as a whole category, while few
prognostic studies were addressed at non-follicular
low-grade NHL,12-14 and none analyzed the possibil-
ity of validating the IPI in this NHL category.
So far, in prospective therapeutic studies the Grup-
po Italiano per lo Studio dei Linfomi (GISL) has stratified
patients affected with low-grade NHL, WF group A,
according to a definition of indolent or aggressive
disease specifically designed for this histotype, main-
ly based on parameters commonly used for the prog-
nostic evaluation of patients with chronic lympho-
cytic leukemia patients.
The present retrospective study was aimed at eval-
uating the prognostic power of the IPI in the specific
subset of low-grade non-follicular NHL (WF group A)
in terms of survival, response to therapy and response
duration. In addition, the accuracy of the prognostic
criteria previously employed in GISL therapeutic stud-
ies with regards to the final outcome of these patients
is reported.
Design and Methods
From 1988 to 1995 256 patients affected by low-
grade NHL, WF group A, were reported to the GISL
Lymphoma Registry from 15 co-operative Institu-
tions. A proportion of these patients was included in
current prospective therapeutic GISL trials. In 137
(55.7%) and 122 (47.6%) cases the clinical informa-
tion available at diagnosis allowed classification
according to the IPI and the GISL definition of indo-
lent or aggressive presentation, respectively. The
median age of the evaluable cases was 65.8 years
(range 26-84) and 79 cases were males. At the time
of the present evaluation (May 1998) the median
observation was 44.9 months, the median overall
survival of the evaluable cases was 117 months with
45% of patients alive at 10 years.
The IPI system was applied according to the origi-
nal scheme which takes into account four unfavor-
able parameters (age over 60, high LDH, perfor-
mance status >1, number of extranodal sites >1) and
stratifies patients in four risk groups, low (L), inter-
mediate-low (IL), intermediate-high (IH) and high
(H) risk.
Patients were also stratified into three IPI risk
groups, by pooling the data of cases classified as IL
and IH risk in the original scheme into a single group.
According to the GISL prognostic classification,
patients were defined as presenting with aggressive
disease if they had at least one of the following fea-
tures: B symptoms, bulky lesion (> 5 cm), Hb < 10
g/dL, platelet count < 100109/L, or diffuse pattern
of neoplastic infiltration at bone marrow biopsy.
Patients without any of these features were defined as
having indolent disease. The additional parameter of
a short doubling time of the tumor burden, usually
considered in prospective therapeutic GISL trials, was
not evaluated in the present retrospective analysis.
In all patients the histology was documented from
the biopsy of involved tissue and clinical staging was
performed by common investigations which includ-
ed CT scan and bone marrow biopsy. Response to
therapy was also defined according to currently used
criteria.15
The main clinical features, the distribution of
patients in both prognostic systems, and the thera-
peutic approaches are reported in Table 1. In detail,
treatment consisted mainly of single agent therapy
with chlorambucil with or without prednisone; a
minority of patients received anthracycline-contain-
ing combination chemotherapy. In 15 cases a watch-
and-wait policy was used; so far, only one of these
patients has required chemotherapy.
Statistical analysis
Overall survival was calculated from diagnosis to
death of any cause, and response duration was eval-
uated on complete and partial responders from the
date of response to the date of relapse or progres-
sion. Pearson’s chi-square and Fisher’s exact test (2-
tail) for 22 tables were used for overall comparisons
of clinical complete response (CR) + partial response
(PR) versus no response (NR) + progressive disease
(PD). Survival was calculated by Kaplan and Meier’s
method. Differences in survival between prognostic
groups was evaluated in univariate analysis by the
log-rank test, and the respective influence on survival
of the different variables, significant at p < 0.05, was
calculated in a stepwise fashion according to the Cox
regression method. All calculations were performed
using the SPSS for windows, release 7.0, 1995. 
Results
Survival
International Prognostic Index (IPI)
The distribution of patients between the four orig-
inal IPI risk groups, reported in Table 1, appears
rather unbalanced, because of the very few cases (6%)
classified in the H risk subset, while intermediate risk
presentation was largely prevalent (75%).
The median overall survival of 137 patients evalu-
able for the IPI was 117.1 months (Figure 1). After
stratification according to the four IPI risk groups,
the overall survival rate at 8 years was 83%, 53% and
36% for L, IL and IH risk subsets, respectively; H risk
patients displayed 7.4 months of median survival.
The difference between these groups was highly sig-
nificant (p=0.0005) (Figure 2A). 
Because of the similar behavior of IL and IH
patients, especially in the first years of the disease,
these two subsets were pooled and a simplified mod-
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el with H, intermediate (I) and L risk was designed.
This simplified IPI model predicted survival at a high-
ly significant level (p=0.0002), with a median survival
of 7.4 and 94.9 months and not reached by 168
months for H, I and L subsets, respectively (Figure 2B).
Indolent and aggressive disease according to GISL criteria
By dividing patients according to indolent or
aggressive disease presentation, as defined by GISL
criteria, a significant difference in overall survival was
demonstrated (p = 0.0107) (Figure 3). The median
survival was 71.3 months (CI 62.08-80.59) for
patients with aggressive disease versus a not reached
median survival for the indolent subgroup. The sur-
vival rate at 4 and 8 years was 79% and 62% for the
latter subset and 62% and 43% for cases with aggres-
sive disease.
A multivariate analysis was performed taking into
account the simplified IPI, the indolent and aggressive
presentation and sex, which is a parameter not incor-
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Table 1. Main data of the present series.
No. of cases reported to the GISL registry 256
No. of evaluable cases 137
Median age, years (range) 65.8 (26-84)
Male/female 79/58
Median follow-up (months) 44.9
Median survival (months) 117.07





Distribution by GISL No. %
Prognostic categories
indolent disease 65 53.3
aggressive disease 57 46.7
No. of evaluable cases treated 71
with single agent 40
with regimens without anthracycline 20
with regimens with anthracycline 9
other therapy 2
Figure 1. Overall survival of the present series of low-grade
non-follicular lymphoma patients.
Figure 3. Overall survival of patients divided according to
indolent and aggressive presentation as defined by GISL cri-
teria.
Figure 2. Overall survival of patients stratified according to
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porated in the above mentioned systems. It is note-
worthy that both prognostic models independently
and statistically significantly predicted survival (Table
2). Therefore, we designed a score system integrating
the simplified IPI and GISL systems. By giving score 0
to indolent disease by GISL and IPI low risk, score 1
to aggressive disease by GISL and intermediate risk by
simplified IPI and score 2 to IPI high risk, a system
including three prognostic groups with Score 0, Score
1 and Score 2 or 3 patients is obtained. As reported
in Figure 4, this score system allows a more balanced
distribution of patients with highly significant differ-
ence in overall survival (p=0.0014). 
Response to therapy and duration of response
Response to therapy, evaluable in 51.8% of patients,
was analyzed by comparing responders (complete and
partial) versus non-responders. The response rate
ranged from 80 to 87.5% without a significant differ-
ence by type of therapy (data not shown). When the
impact of sex, indolent or aggressive disease presen-
tation and simplified IPI was assessed, only the last
variable resulted to have significant prognostic power
in univariate analysis (Table 3). 
The median duration of response was 48 months
(CI 29-67). None of the above-considered prognos-
tic factors had a significant impact on this parame-
ter (data not shown).  
Discussion
Accurate assessment of the prognostic features at
presentation is mandatory in low-grade NHL because
of the wide variability of therapeutic options: indeed
the choice is even wider than in aggressive histology,
since approaches such as watch-and-wait, biological
response modifiers, and monoclonal antibodies, can
appropriately be employed in low-grade subsets.
Moreover, the use of high dose chemotherapy with
stem cell rescue in younger patients requires correct
prognostic evaluation of individual cases, taking into
account the possibility of a long survival in spite of it
being almost impossible to achieve disease eradica-
tion with conventional therapy.
In this respect, many prognostic factors in low-
grade NHL have been identified and some prognos-
tic systems have been proposed, mainly concerning
follicular histology,4-6 but none of them has gained
general agreement and is currently used for thera-
peutic stratification. More recently, the IPI, original-
ly designed for aggressive lymphoma, has been vali-
dated in indolent diseases.8-11 These studies evaluat-
ed either all low-grade NHL as a whole, or specifi-
cally follicular lymphoma. As far as the subset of non-
follicular low-grade NHL is concerned, previous stud-
ies identified nodal architecture, large cell presence,
stage, systemic symptoms, performance status, LDH,
and 2-microglobulin as prognostic factors influenc-
ing survival,12-14,16 but neither a specific prognostic
system nor the validation of the IPI has been report-
ed for this category. 
The present study considered only WF group A
patients and, in spite of the possible variety of differ-
ent entities included in this NHL subgroup, validated
the IPI system as a reliable predictor of survival and
response rate. In fact, the analysis by IPI risk group
showed that H risk cases had a median survival of 7.4
months, while 83%, 53%, 36% of patients with L, IL,
IH patients, respectively, were alive at 8 years. Like a
previously reported study,10 our series includes
patients from a lymphoma registry, thus not always
eligible for clinical trials; the two series differ in the
longer survival of H risk cases in the population stud-
ied by Hermans et al.10 The difference of survival was
highly significant and confirmed by both univariate
and multivariate analyses. 
A more detailed analysis of the survival curves
showed that both intermediate groups had a similar
IPI in non-follicular indolent NHL
Figure 4. Overall survival of patients stratified by integrat-













Table 2. Multivariate analysis of parameters influencing
overall survival. 
Variable X2 p* RR (95% C.I.)
GISL prognostic categories
(indolent vs aggressive) 4.74 0.0293 2.0 (1.0-3.7)
Simplified IPI
(low vs intermediate v high) 15.13 0.0001 4.3 (2.0-8.9)
*Cox regression analysis.
Table 3. Univariate analysis of prognostic variables for clin-
ical response. 
Variable CR+PR NR+PD *Univariate p 
Age, years (≤ 60 v > 60) 20 v 37 3 v 7 NS
Sex (male vs female) 34 v 21 7 v 3 NS
GISL prognostic categories
(indolent vs aggressive) 26 v 22 2 v 5 NS
Simplified IPI
(low vs intermediate vs high) 13 v 42 v 2 0 v 6 v 4 0.001
*Pearson’s chi-square; NS: not significant.
behavior, especially in the first two years of follow-up.
This observation prompted us to merge the two
groups and to verify the validity of a simplified IPI
model consisting of 3 prognostic groups (high, inter-
mediate and low risk). As reported for follicular
NHL,9 this model was of significantly prognostic val-
ue in terms of survival and response rate.
The similar behavior of the intermediate risk groups
and the unbalanced distribution of patient between
the IPI categories, with the vast majority of cases clas-
sified as being intermediate risk and very few cases as
high risk, hamper the extended use of the IPI model
alone in this histologic subgroup and suggest the need
to consider additional prognostic stratifications.
For this purpose we validated in this series the prog-
nostic accuracy of the definition of indolent and
aggressive disease used in the GISL prospective trials,
a definition which is based on criteria completely dif-
ferent from the IPI factors and more similar to the
prognostic parameters commonly employed for CLL,
this disease being very close to lymphocytic NHL. The
present study confirmed the significant and indepen-
dent prognostic power in terms of survival of the GISL
definition of indolent and aggressive disease with 8-
year survival rates of 62% and 43% of cases, respec-
tively. Moreover, the integration of GISL system and IPI
simplified model results in a prognostic score which
could be useful to identify patients at different risks
with a balanced distribution between these groups,
although it should be verified on a larger series. 
Unfortunately, the retrospective character of the
present study, dealing with a relatively rare subset of
NHL, and requiring an adequate period of observa-
tion, did not allow the analysis of the prognostic sig-
nificance of newly identified biological features such as
cytogenetics, p53, molecular markers and soluble fac-
tors.
In conclusion, in the absence of information on rel-
evant biological parameters, the validation of IPI in
indolent non-follicular NHL, improved by the addi-
tion of specific variables, i.e. the GISL criteria, could
be of value to identify among WF group A NHL
patients eligible for a watch-and-wait policy in IPI L risk
group, patients potentially eligible for up-front very
intensive approaches in an IPI H risk setting and in the
IPI I group with aggressive presentation of the disease,
while conventional treatment can be offered as the
treatment of choice for the remaining IPI I cases.
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